
Trump orders drug stockpile, increased manufacturing
President Donald Trump ordered administration officials to draw up a list of 26 key drugs to develop a stockpile in the United States.
His executive order provides for a six month supply of the active pharmaceutical ingredients in each drug to be added to the Strategic Active Pharmaceutical Reserve.
“Stockpiling APIs is advantageous as APIs are generally lower-cost and have longer shelf lives than the finished drug products they make,” Trump’s order reads.
“Filling the SAPIR will also insulate the United States from the concentration of foreign, sometimes adversary, nations in the world-wide supply of the Key Starting Materials used to make APIs.”
The first Trump administration established SAPIR to serve as a national stockpile of ingredients for the production of essential medicines. SAPIR is overseen by the Office of the Assistant Secretary for Preparedness and Response.
In President Joe Biden’s administration, ASPR curated a list of 86 medicines deemed “critically needed for acute patient care.”
The Biden administration list included fentanyl for pain relief, HIV treatments like Bictegravir and regular insulin.
Trump’s directive gives ASPR 30 days to create a reduced drug list from the Biden administration’s with a focus on increasing domestic curation of the drugs.
The order follows the U.S. Food and Drug Administration’s announcement last week of the FDA Precheck program which is designed to expedite the drug manufacturing approval processes.
In the announcement, the FDA said 11% of active pharmaceutical ingredients are produced by U.S. manufacturers.
To increase production, the FDA will begin to offer more frequent communication between regulatory agencies and manufacturers in the development of domestic production sites.
“The FDA PreCheck initiative is one of many steps FDA is taking that can help reverse America’s reliance on foreign drug manufacturing and ensure that Americans have a resilient, strong, and domestic drug supply,” said FDA Commissioner Marty Makary.
Trump has also increased pressure on pharmaceutical companies to invest in more domestic production over the past few months.
In July, Trump sent letters to 18 pharmaceutical companies, including Pfizer and Johnson and Johnson, demanding they outline steps to bring down prices of prescription drugs in the United States.
He has also touted billions of dollars in investments from pharmaceutical companies over the last six months including $500 billion from Johnson and Johnson, $50 billion from AstraZeneca and $10 billion from Abbvie.
In what appears to be aligned with the Trump administration’s priorities, Abbvie confirmed part of its investment will go to a $195 million site in North Chicago dedicated to producing active pharmaceutical ingredients in the U.S.
“This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients’ lives,” said Robert Michael, CEO of Abbvie.
Latest News Stories

Bill would codify Trump’s executive order banning ‘woke’ debanking

Illinois quick hits: Pritzker sends bill back to legislature; cannabis loans announced

Dem, GOP candidates begin signature-gathering for 2026

‘All hands on deck:’ Burrow says AWOL Democrats being pursued to be arrested

Dems say EPA cancelling $7B community solar grants ‘illegal,’ but ignore law

Attorney argues IL should honor TX warrants for absconding Dems

WATCH: Legislators urge return to capitol to deal with increasing Illinois energy costs

Parental rights groups concerned over DEI in Denver teacher contract

WATCH: Homeland Secretary: Pritzker, Johnson are protecting dangerous criminals

Reports: DOJ probing NY AG’s fraud case against Trump

Trump warns of ‘Great Depression’ if appeals court curbs tariff power

Illinois in focus: DHS announces new facility; NFIB urges veto of regulations; minority scholarship lawsuit moves forward
